Longer RFS with Nivolumab Than with Ipilimumab Among Patients with Resected Stage IIIB-C or Stage IV Melanoma By Ogkologos - February 2, 2026 4 0 Facebook Twitter Google+ Pinterest WhatsApp Final data from the CheckMate 238 study Source RELATED ARTICLESMORE FROM AUTHOR 2026 ESMO TAT Honorary Award Recipient Announced Sacituzumab Govitecan Plus Pembrolizumab Prolongs PFS Among Patients with Previously Untreated, PD-L1-positive, Advanced TNBC FDA Grants Regular Approval to Rucaparib for Metastatic Castration-Resistant Prostate Cancer MOST POPULAR How Some Brain Tumors Hijack the Mind to Grow June 21, 2023 Respuestas a sus preguntas sobre la vacuna contra el COVID-19 March 12, 2021 Embrace Your Inner Flexibility March 29, 2021 A Blood-Based, Multigenomic Signature is an Effective Diagnostic and Has Clinical... August 16, 2021 Load more HOT NEWS Mom Credits Baby with Saving Her Life After She was Diagnosed... ASCO20 Virtual Research Round Up Podcast: Breast Cancer, Sarcoma, and Supportive... Breaking News: The Healthcare Marketplace Re-opens TODAY! Sharing Energy
